Inovio Pharmaceuticals Inc (INO)

[Ubertino]

Inovio Pharmaceuticals, Inc. Analyst Rating Update

By Ducis Corddry - May 26, 2015

Research firm Zacks has rated Inovio Pharmaceuticals (NASDAQ:INO) and has ranked it at 2, indicating that for the short term the shares are a buy. 6 Wall Street analysts have given the company an average rating of 1. Strong buy was given by 6 Wall Street Analysts.

HC Wainwright initiates coverage on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) . The global brokerage major announces a current price target of $17 per share. Analysts at the HC Wainwright have a current rating of Buy on the shares. Inovio Pharmaceuticals, Inc. (NASDAQ:INO): The mean estimate for the short term price target for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) stands at $21 according to 6 Analysts. The higher price target estimate for the stock has been calculated at $31 while the lower price target estimate is at $17.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) rose 6.9% or 0.57 points on Friday and made its way into the gainers of the day. After trading began at $8.27 the stock was seen hitting $8.89 as a peak level and $8.2 as the lowest level. The stock ended up at $8.83. The daily volume was measured at 2,486,216 shares. The 52-week high of the share price is $14.2 and the 52-week low is $6.3299. The company has a market cap of $634 million.

http://newswatchinternational.com/news/inovio-pharmaceuticals-inc-analyst-rating-update.html